Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P29320
UPID:
EPHA3_HUMAN
Alternative names:
EPH-like kinase 4; HEK; Tyrosine-protein kinase TYRO4; Tyrosine-protein kinase receptor ETK1
Alternative UPACC:
P29320; Q9H2V3; Q9H2V4
Background:
Ephrin type-A receptor 3, known by alternative names such as EPH-like kinase 4 and Tyrosine-protein kinase receptor ETK1, plays a pivotal role in various cellular processes. This receptor tyrosine kinase engages in bidirectional signaling by binding with ephrin family ligands, influencing cell-cell adhesion, cytoskeletal organization, and cell migration. It is crucial in cardiac development, retinotectal mapping, and neuromuscular circuit formation.
Therapeutic significance:
Given its involvement in colorectal cancer, characterized by malignant lesions in the colon and rectum, Ephrin type-A receptor 3 presents a promising target for therapeutic intervention. Understanding its role could open doors to novel strategies for managing this complex disease.